Tarsus Launches Xdemvy (lotilaner ophthalmic solution) for the Treatment of Demodex Blepharitis
Shots:
- The company reported the commercial availability of Xdemvy (lotilaner ophthalmic solution) 0.25% at pharmacies nationwide for prescription. Patients will administer one drop per eye, twice a day (~12hrs apart) for 6wks.
- The product was approved in the US making it the first and only approved treatment for Demodex blepharitis, based on data from two, 6wk. (Saturn-1 & 2) trial meeting their 1EPs & 2EPs with no serious AEs
- The company has established a patient assistance program called Tarsus Connect to help eligible patients gain access to Xdemvy. Xdemvy is a novel prescription eye drop for Demodex blepharitis that targets and eradicates the root cause of the disease, Demodex mite infestation
Ref: Globenewswire | Image: Tarsus Pharmaceuticals
Related News:- Pfizer’s Elrexfio Receives the US FDA’s Accelerated Approval for Relapsed or Refractory Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
